Results of a Retrospective and Multicenter Study on the Treatment of Relapses in Myeloid Hemopathies Using Donor Lymphocyte Infusion

Introduction: Post-transplant relapses of hematological malignancies have a poor prognosis. The aim of this study is to evaluate the outcome of these patients who received DLI in this setting. Material and methods: We conducted a multicenter retrospective study in the SFGM-TC centers including all patients who received at least one DLI for the management of post-transplant relapse of AML, MDS and Myelofibrosis. We evaluated the outcome of the overall cohort and then determined the variables favorably or unfavorably influencing prognosis after DLI. Results: 434 patients were included. Median follow-up was 231 days. Overall survival at 1, 2, and 5 years was 45%, 32%, and 20%, respectively. Overall survival was better in patients with NPM1-mutated AML (p = 0.03), in patients who relapsed late (p

Introduction: Post-allograft relapses of acute myeloid hemopathy have a poor prognosis. The objective of this study is to evaluate the future of these patients who have benefited from DLI in this context. Material and method: we conducted a retrospective multicenter study within the centers of the SFGM-TC including all the patients who received at least one DLI for the management of a post allograft relapse of AML, MDS and Myelofibrosis. We evaluated the outcome of the overall cohort and then determined the variables favorably or unfavorably influencing the prognosis after DLI. Results: 434 patients were included. The median follow-up was 231 days. Overall survival at 1, 2 and 5 years was 45%, 32% and 20% respectively. Overall survival was better in patients with AML with an NPM1 mutation (p = 0.03), in patients who relapsed late (p